Extensions to the Visual Predictive Check to facilitate model performance evaluation

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 35, Issue 2, 2008, Pages 185-202

  Post, Teun M ^a   Freijer, Jan I ^d   Ploeger, Bart A ^b,c   Danhof, Meindert ^b,c  

^a NV ORGANON   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c Leiden Advanced Pharmacokinetics and Pharmacodynamics (LAP and P) Consultants   (Netherlands)

^d Astellas Pharma Global Development   (Netherlands)

Author keywords

Disease progression; Evaluation; Model performance; Pharmacodynamics; Pharmacokinetics; Qualification; Validation; Visual Predictive Check

Indexed keywords

PIOGLITAZONE;

ARTICLE; BOOTSTRAPPING; COMPARTMENT MODEL; DISEASE COURSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL METHOD; PHARMACODYNAMICS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; SIMULATION; VALIDATION PROCESS; VISUAL PREDICTIVE CHECK;

ALGORITHMS; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MODELS, STATISTICAL; NONLINEAR DYNAMICS; PHARMACOKINETICS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SOFTWARE;

EID: 43949145260     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-007-9081-1     Document Type: Article

References (23)

1. Bhattaram AV et al (2007) Impact of pharmacometrics review on new drug approval and labeling decisions - a survey of 31 new drug applications. Clin Pharmacol Ther 81: 213-221
2. Sheiner LB, Steimer JL (2000) Pharmacokinetic/pharmacodynamic modelling in drug development. Annu Rev Pharmacol Toxicol 40: 67-96
3. Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA et al (2007) Model-based drug development. Clin Pharmacol Ther 82(1): 21-32
4. Chan PL, Holford NH (2001) Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 41: 625-659
5. Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61(3): 275-291
6. Brendel K, Dartois C, Comets E et al (2007) Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated?: a survey of the literature from 2002 to 2004. Clin Pharmacokinet 46(3): 221-234
7. Holford N (2005) The Visual Predictive Check - Superiority to Standard Diagnostic (Rorschach) Plots. PAGE 14, Abstr 738 [http://www.page-meeting.org/? abstract=972]
8. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/ pharmacodynamic models using the Posterior Predictive Check. J Pharmacokin Pharmacodynam 28(2): 171-192
9. Jadhav PR, Gobburu JVS (2005) A new equivalence based metric for predictive check to qualify mixed-effects models. AAPS J 7(3): E523-E531
10. Winter W, DeJongh J, Post T et al (2006) A mechanism-based disease model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J Pharmacokin Pharmacodynam 33(3): 313-343
11. Holford NHG, Chan PLS, Nutt JG, Kieburtz K, Shoulson I, Parkinson Study Group (2006) Disease progression and pharmacodynamics in Parkinson Disease - evidence for functional protection with levodopa and other treatments. J Pharmacokin Pharmacodynam 33:281-311
12. Post TM, Freijer JI, de Winter W et al (2006) Accurate interpretation of the visual predictive check in order to evaluate model performance PAGE 15, Abstr 972 [http://www.page-meeting.org/?abstract=972]
13. Holford N, Pillai G, Kaila N et al (2006) PKPD model for cathepsin K inhibition with balicatib and changes in bone turnover biomarkers, in particular NTx PAGE 15 Abstr 1015 [http://www.page-meeting.org/?abstract=1015]
14. Fang L, Holford NHG, Hinkle G et al (2007) Population pharmacokinetics of humanized monoclonal antibody HuCC49ΔCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol 47(2): 227-237
15. Urien S, Holford N (2007) R for NONMEM. https://sourceforge.net/project/ showfiles.php?group_id=29501&package_id=140129&release_id=538680
16. Mentré F, Escolano S (2006) Prediction discrepancies for the evaluation of nonlinear mixed-effects models. J Pharmacokin Pharmacodynam 33(3): 345-367
17. Gelman A, Mechelen I, Verbeke G et al (2005) Multiple imputation for model checking: completed-data plots with missing and latent data. Biometrics 61: 74-85
18. Sheiner LB, Beal SL, Dunne A (1997) Analysis of nonrandomly censored ordered categorical longitudinal data from analgesic trials. J Am Stat Assoc 92: 1235-1255
19. Brendel K, Comets E, Laffont C, Laveille C, Mentré F (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23(9): 2036-2049
20. Hu C, Sale ME (2003) A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokin Pharmacodynam 30(1): 83-103
21. Hing JP, Woolfrey SG, Greenslade D, Wright PMC (2001) Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data. J Pharmacokin Pharmacodynam 28(5): 465-479
22. Unnebrink K, Windeler J (2001) Intention-to-treat methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med 20: 3931-3946
23. Tan M, Baski A et al (2005) Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 28: 544-550